FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to pyridyl ketone derivatives of formula (I) or pharmaceutically acceptable salts thereof: 
where: R1 is selected from the group consisting of phenyl and pyridyl, where independently of each other, each of phenyl and pyridyl is optionally substituted with one or more groups, selected from the group consisting of halogen, alkyl, haloalkyl, -OR7, -C(O)R7, -C(O)NHR7, -NHC(O)R7, -NHC(O)OR7 and -NHS(O)mR7; R2 is hydrogen; R3 is selected from the group consisting of hydrogen and alkyl, wherein alkyl is optionally substituted with one or more groups selected from the group consisting of -OR7; R4 is phenyl, where the phenyl is optionally substituted with one or more groups selected from the group consisting of halogen and alkyl; R5 is selected from the group consisting of hydrogen and alkyl; R6 is selected from the group consisting of hydrogen, halogen and alkyl; R7 is selected from the group consisting of hydrogen, alkyl, C3-6cycloalkyl, 5- or 6-membered heterocyclyl, wherein, independently of each other, each of said radicals is optionally substituted with one or more groups selected from the group consisting of alkyl and halogen; wherein the heterocyclyl contains one or two heteroatoms selected from the group consisting of N, O and S(O)m; independently of each other, each of the R8 and R9 is selected from the group consisting of hydrogen or alkyl; and m is 2, and use thereof as MEK inhibitors, and especially as therapeutic agents for the treatment of cancer.
EFFECT: disclosed are novel pyridone derivatives, preparation method thereof, pharmaceutical compositions containing the same, and their use as MEK inhibitors, and especially as therapeutic agents for cancer.
12 cl,4 tbl, 33 ex
